Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program.
Pharmaceutical Technology on MSN
SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal
The deal provides SanegeneBio with an upfront payment of $200m.
Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of SanegeneBio’s ...
The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA ...
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...
Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Genentech Inc. is paying $200 million up front and up to $1.5 billion in milestone payments to license one of Suzhou Sanegene Bio Inc.’s RNAi programs. Metabolic and autoimmune-focused Sanegene did ...
RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results